Senores Pharmaceuticals zoom nearly 6% on entering into SPA to acquire 2.97% stake in Havix

Shares of Senores Pharmaceuticals rallied over 3% despite broader weakness in the market as the company announced a strategic share purchase agreement with Havix Group Inc.

Senores Pharmaceuticals has entered into the Share Purchase Agreement (SPA) with one of the shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (Havix) for the acquisition of 6730 equity shares of Havix, i.e. 2.97% of the total paid-up share capital of Havix and subject to the terms and conditions as mentioned in the SPA.

Further, post the aforesaid acquisition, the aggregate shareholding of the company (along with the shareholding of its wholly owned subsidiary - Senores Pharmaceuticals Inc.) in Havix will increase from 70.07% to 73.04%.

The Management Committee of the Board of Directors of the company, in their meeting held on July 10, 2025, has approved the same.

Havix is a US-based company engaged in the business of developing, manufacturing and supplying various finished formulations.

In Q4FY25, the revenue for the quarter jumped 11.4% YoY to ₹114 crore as compared to ₹102 crore in the previous year’s similar quarter. The EBITDA for the quarter declined 13% YoY to ₹19.4 crore as against ₹25.6 crore in the same quarter last year. The net profit jumped 26% YoY to ₹18 crore as compared to ₹14.1 crore in the previous year’s similar quarter.

In March, Senores Pharmaceuticals, Inc., USA (SPI), signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt.The market size of Enalapril Tablet in the USA was around $28.60 million (MAT December 2024) as per IQVIA and around $109.24 million (MAT March 2025) as per the specialty data aggregator Symphony

Senores Pharmaceuticals is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment, predominantly for the Regulated Markets across various therapeutic areas and dosage forms.